Your browser doesn't support javascript.
loading
Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States.
Garrett, Giorgia L; Blanc, Paul D; Boscardin, John; Lloyd, Amanda Abramson; Ahmed, Rehana L; Anthony, Tiffany; Bibee, Kristin; Breithaupt, Andrew; Cannon, Jennifer; Chen, Amy; Cheng, Joyce Y; Chiesa-Fuxench, Zelma; Colegio, Oscar R; Curiel-Lewandrowski, Clara; Del Guzzo, Christina A; Disse, Max; Dowd, Margaret; Eilers, Robert; Ortiz, Arisa Elena; Morris, Caroline; Golden, Spring K; Graves, Michael S; Griffin, John R; Hopkins, R Samuel; Huang, Conway C; Bae, Gordon Hyeonjin; Jambusaria, Anokhi; Jennings, Thomas A; Jiang, Shang I Brian; Karia, Pritesh S; Khetarpal, Shilpi; Kim, Changhyun; Klintmalm, Goran; Konicke, Kathryn; Koyfman, Shlomo A; Lam, Charlene; Lee, Peter; Leitenberger, Justin J; Loh, Tiffany; Lowenstein, Stefan; Madankumar, Reshmi; Moreau, Jacqueline F; Nijhawan, Rajiv I; Ochoa, Shari; Olasz, Edit B; Otchere, Elaine; Otley, Clark; Oulton, Jeremy; Patel, Parth H; Patel, Vishal Anil.
Afiliação
  • Garrett GL; University of California-San Francisco Medical Center, San Francisco.
  • Blanc PD; University of California-San Francisco Medical Center, San Francisco.
  • Boscardin J; University of California-San Francisco Medical Center, San Francisco.
  • Lloyd AA; Scripps Green Hospital, La Jolla, California.
  • Ahmed RL; University of Minnesota Medical Center, Minneapolis.
  • Anthony T; Baylor All Saints and Baylor University Medical Center, Dallas, Texas.
  • Bibee K; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Breithaupt A; University of California-Los Angeles Medical Center, Los Angeles.
  • Cannon J; Mayo Clinic Florida, Jacksonville.
  • Chen A; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Cheng JY; Yale New Haven Hospital, New Haven, Connecticut.
  • Chiesa-Fuxench Z; University of Pennsylvania, Philadelphia.
  • Colegio OR; Yale New Haven Hospital, New Haven, Connecticut.
  • Curiel-Lewandrowski C; University of Arizona Medical Center, Tucson.
  • Del Guzzo CA; New York Presbyterian/Columbia University Medical Center, New York.
  • Disse M; University of Minnesota Medical Center, Minneapolis.
  • Dowd M; New York Presbyterian/Columbia University Medical Center, New York.
  • Eilers R; University of California-San Diego Medical Center, San Diego.
  • Ortiz AE; University of California-San Diego Medical Center, San Diego.
  • Morris C; Barnes-Jewish Hospital, St Louis, Missouri.
  • Golden SK; Oregon Health and Science University, Portland.
  • Graves MS; Scripps Green Hospital, La Jolla, California.
  • Griffin JR; Baylor All Saints and Baylor University Medical Center, Dallas, Texas.
  • Hopkins RS; Oregon Health and Science University, Portland.
  • Huang CC; University of Alabama Hospital, Birmingham.
  • Bae GH; Baylor All Saints and Baylor University Medical Center, Dallas, Texas.
  • Jambusaria A; Mayo Clinic Florida, Jacksonville.
  • Jennings TA; University of Alabama Hospital, Birmingham.
  • Jiang SI; University of California-San Diego Medical Center, San Diego.
  • Karia PS; Brigham and Women's Hospital, Boston, Massachusetts.
  • Khetarpal S; Cleveland Clinic Foundation, Cleveland, Ohio.
  • Kim C; Mayo Clinic Rochester, Rochester, Minnesota.
  • Klintmalm G; Baylor All Saints and Baylor University Medical Center, Dallas, Texas.
  • Konicke K; Medical College of Wisconsin, Milwaukee.
  • Koyfman SA; Cleveland Clinic Foundation, Cleveland, Ohio.
  • Lam C; Cleveland Clinic Foundation, Cleveland, Ohio.
  • Lee P; University of Minnesota Medical Center, Minneapolis.
  • Leitenberger JJ; Oregon Health and Science University, Portland.
  • Loh T; University of California-San Diego Medical Center, San Diego.
  • Lowenstein S; University of California-San Francisco Medical Center, San Francisco.
  • Madankumar R; New York University Langone Medical Center, New York.
  • Moreau JF; Brigham and Women's Hospital, Boston, Massachusetts.
  • Nijhawan RI; University of Texas Southwestern Medical Center, Parkland Memorial Hospital, Dallas.
  • Ochoa S; Mayo Clinic Arizona, Phoenix.
  • Olasz EB; Medical College of Wisconsin, Milwaukee.
  • Otchere E; Scripps Green Hospital, La Jolla, California.
  • Otley C; Mayo Clinic Rochester, Rochester, Minnesota.
  • Oulton J; University of Arizona Medical Center, Tucson.
  • Patel PH; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Patel VA; New York Presbyterian/Columbia University Medical Center, New York.
JAMA Dermatol ; 153(3): 296-303, 2017 03 01.
Article em En | MEDLINE | ID: mdl-28097368
Importance: Skin cancer is the most common malignancy occurring after organ transplantation. Although previous research has reported an increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has estimated the posttransplant population-based incidence in the United States. Objective: To determine the incidence and evaluate the risk factors for posttransplant skin cancer, including squamous cell carcinoma (SCC), melanoma (MM), and Merkel cell carcinoma (MCC) in a cohort of US OTRs receiving a primary organ transplant in 2003 or 2008. Design, Setting, and Participants: This multicenter retrospective cohort study examined 10 649 adult recipients of a primary transplant performed at 26 centers across the United States in the Transplant Skin Cancer Network during 1 of 2 calendar years (either 2003 or 2008) identified through the Organ Procurement and Transplantation Network (OPTN) database. Recipients of all organs except intestine were included, and the follow-up periods were 5 and 10 years. Main Outcomes and Measures: Incident skin cancer was determined through detailed medical record review. Data on predictors were obtained from the OPTN database. The incidence rates for posttransplant skin cancer overall and for SCC, MM, and MCC were calculated per 100 000 person-years. Potential risk factors for posttransplant skin cancer were tested using multivariate Cox regression analysis to yield adjusted hazard ratios (HR). Results: Overall, 10 649 organ transplant recipients (mean [SD] age, 51 [12] years; 3873 women [36%] and 6776 men [64%]) contributed 59 923 years of follow-up. The incidence rates for posttransplant skin cancer was 1437 per 100 000 person-years. Specific subtype rates for SCC, MM, and MCC were 812, 75, and 2 per 100 000 person-years, respectively. Statistically significant risk factors for posttransplant skin cancer included pretransplant skin cancer (HR, 4.69; 95% CI, 3.26-6.73), male sex (HR, 1.56; 95% CI, 1.34-1.81), white race (HR, 9.04; 95% CI, 6.20-13.18), age at transplant 50 years or older (HR, 2.77; 95% CI, 2.20-3.48), and being transplanted in 2008 vs 2003 (HR, 1.53; 95% CI, 1.22-1.94). Conclusions and Relevance: Posttransplant skin cancer is common, with elevated risk imparted by increased age, white race, male sex, and thoracic organ transplantation. A temporal cohort effect was present. Understanding the risk factors and trends in posttransplant skin cancer is fundamental to targeted screening and prevention in this population.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma de Células Escamosas / Carcinoma de Célula de Merkel / Transplante de Órgãos / Melanoma Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma de Células Escamosas / Carcinoma de Célula de Merkel / Transplante de Órgãos / Melanoma Idioma: En Ano de publicação: 2017 Tipo de documento: Article